## Susumu Ogawa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/234210/publications.pdf

Version: 2024-02-01

29 papers 938 citations

759233 12 h-index 27 g-index

29 all docs 29 docs citations

29 times ranked 1376 citing authors

#	Article	IF	CITATIONS
1	Electrolyzed hydrogen-rich water for oxidative stress suppression and improvement of insulin resistance: a multicenter prospective double-blind randomized control trial. Diabetology International, 2022, 13, 209-219.	1.4	12
2	Diabetes care providers' manual for disaster diabetes care. Diabetology International, 2019, 10, 153-179.	1.4	6
3	Diabetes Care Providers' Manual for Disaster Diabetes Care. Journal of Diabetes Investigation, 2019, 10, 1118-1142.	2.4	5
4	Effects of sodiumâ€glucose cotransporter 2 inhibitors on hypoglycaemia in brittle diabetic patients with decreased endogenous insulin secretion. Endocrinology, Diabetes and Metabolism, 2019, 2, e00044.	2.4	0
5	Achieving LDL cholesterol target levels <1.81 mmol/L may provide extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study. Diabetes, Obesity and Metabolism, 2019, 21, 791-800.	4.4	15
6	Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care, 2018, 41, 1275-1284.	8.6	43
7	Decreased Glycaemia with Renal Failure in Diabetes Betides in Relation to the Change in Renal Glutamate Metabolism. Journal of Clinical & Experimental Nephrology, 2018, 03, .	0.1	1
8	The relationship between the renal reabsorption of cysteine and the lowered urinary pH in diabetics. Clinical and Experimental Nephrology, 2017, 21, 1044-1052.	1.6	4
9	The Reduction in Urinary Glutamate Excretion Is Responsible for Lowering Urinary pH in Pink Urine Syndrome. Tohoku Journal of Experimental Medicine, 2016, 239, 103-110.	1.2	8
10	Urinary angiotensinogen excretion is associated with blood pressure in obese young adults. Clinical and Experimental Hypertension, 2016, 38, 203-208.	1.3	9
11	Stabilization of postprandial blood glucose fluctuations by addition of glucagon like polypeptideâ€analog administration to intensive insulin therapy. Journal of Diabetes Investigation, 2015, 6, 436-442.	2.4	11
12	Lower urinary pH is useful for predicting renovascular disorder onset in patients with diabetes. BMJ Open Diabetes Research and Care, 2015, 3, e000097.	2.8	10
13	Elucidation of the etiology and characteristics of pink urine in young healthy subjects. Clinical and Experimental Nephrology, 2015, 19, 822-829.	1.6	11
14	A new Classification of Diabetic Nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy. Journal of Diabetes Investigation, 2015, 6, 242-246.	2.4	157
15	The strong relation between post-hemodialysis blood methylglyoxal levels and post-hemodialysis blood glucose concentration rise. Clinical and Experimental Nephrology, 2015, 19, 527-533.	1.6	10
16	A new classification of Diabetic Nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy. Diabetology International, 2014, 5, 207-211.	1.4	10
17	Identification of the Stages of Diabetic Nephropathy at Which Angiotensin II Receptor Blockers Most Effectively Suppress Albuminuria. American Journal of Hypertension, 2013, 26, 1064-1069.	2.0	7
18	A Decline in Glomerular Filtration Rate Rather than Renal Arterial Stenotic Lesions, per se, Predicts Cardiovascular-Renal Events in Type 2 Diabetic Patients. Circulation Journal, 2013, 77, 2816-2822.	1.6	8

#	Article	IF	CITATION
19	Eicosapentaenoic Acid Improves Glycemic Control in Elderly Bedridden Patients with Type 2 Diabetes. Tohoku Journal of Experimental Medicine, 2013, 231, 63-74.	1.2	19
20	Compared with insulin glargine, insulin degludec narrows the day-to-day variability in the glucose-lowering effect rather than lowering blood glucose levels. Journal of Diabetes Mellitus, 2013, 03, 244-251.	0.3	7
21	Effects of the Great East Japan Earthquake and huge tsunami on glycaemic control and blood pressure in patients with diabetes mellitus. BMJ Open, 2012, 2, e000830.	1.9	49
22	Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Decreases Systolic Blood Pressure in Japanese Hypertensive Patients with Type 2 Diabetes. Tohoku Journal of Experimental Medicine, 2011, 223, 133-135.	1.2	100
23	Obese predicts increase in blood pressure associated with enhanced oxidative stress and inflammatory markers in young adults. FASEB Journal, 2011, 25, lb645.	0.5	0
24	Methylglyoxal Is a Predictor in Type 2 Diabetic Patients of Intima-Media Thickening and Elevation of Blood Pressure. Hypertension, 2010, 56, 471-476.	2.7	85
25	Methylglyoxal contributes to the development of insulin resistance and salt sensitivity in Sprague–Dawley rats. Journal of Hypertension, 2009, 27, 1664-1671.	0.5	85
26	Angiotensin II Type 1 Receptor Blockers Reduce Urinary Angiotensinogen Excretion and the Levels of Urinary Markers of Oxidative Stress and Inflammation in Patients with Type 2 Diabetic Nephropathy. Biomarker Insights, 2009, 4, BMI.S2733.	2.5	72
27	Combination Therapy with Renin-Angiotensin System Inhibitors and the Calcium Channel Blocker Azelnidipine Decreases Plasma Inflammatory Markers and Urinary Oxidative Stress Markers in Patients with Diabetic Nephropathy. Hypertension Research, 2008, 31, 1147-1155.	2.7	47
28	SPIRONOLACTONE FURTHER REDUCES URINARY ALBUMIN EXCRETION AND PLASMA B-TYPE NATRIURETIC PEPTIDE LEVLES IN HYPERTENSIVE TYPE II DIABETES TREATED WITH ANGIOTENSIN-CONVERTING ENZYME INHIBITOR. Clinical and Experimental Pharmacology and Physiology, 2006, 33, 477-479.	1.9	22
29	Angiotensin II Type 1 Receptor Blockers Reduce Urinary Oxidative Stress Markers in Hypertensive Diabetic Nephropathy. Hypertension, 2006, 47, 699-705.	2.7	125